Biotechs have underperformed the broader market this year, and these stock are at crossroads as they await the new ...

Novavax is expected to post earnings of $1.13 per share for the current quarter, representing a year-over-year change of ...

Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA approves new vaccine, and revenue guidance is lowered. Vandana Singh FDA Gives ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on ...

Novavax (NVAX) shares soared 19.2% in the last trading session to close at $14.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

The market expects Novavax (NVAX) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus ...

Earlier today, the Food and Drug Administration (FDA) put a clinical hold on the combination and standalone influenza shot developed by Novavax Inc (NASDAQ:NVAX). NVAX is down 17.7% to trade at $ ...

In the latest market close, Novavax (NVAX) reached $10.35, with a +1.97% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.02%.